Drug Pipeline

Lansoprazole 30 mg Once Daily (QD) Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
1
Phase 3
3
Top Sponsors
Active Studies by Phase
Phase 4
1
Phase 3
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07533266 Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced… NSAID (Non-Steroidal Anti-Inflammatory Drug) Not Yet Recruiting
Phase 3
NCT07037875 A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in… GERD (Gastroesophageal Reflux Disease) Recruiting
Not specified
NCT07479056 Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk… Acute Coronary Syndromes (ACS) Recruiting
Sponsors Running Lansoprazole 30 mg Once Daily (QD) Trials
Cinclus Pharma Holding AB (1) SUK MIN SEO (1) Daewoong Pharmaceutical Co. LTD. (1)
Disease Areas
Coronary Artery Disease (1)
Get alerts when Lansoprazole 30 mg Once Daily (QD) trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free